USEFUL LINKS

At the first clinical signs of CHF, use VETMEDIN

VETMEDIN is a versatile, first-line therapy for canine congestive heart failure (CHF). VETMEDIN has been shown to extend survival compared with treatment with angiotensin-converting enzyme (ACE) inhibitors alone^1,2 and to improve quality of life.¹

When used from the start of clinical signs as part of a standard CHF treatment protocol, VETMEDIN keeps dogs going.

VETMEDIN is indicated for the management of the signs of mild, moderate, or severe CHF in dogs due to atrioventricular valvular insufficiency (AVVI) or dilated cardiomyopathy (DCM).^3,4

VETMEDIN is also approved for concurrent use with other cardiac treatments (eg, furosemide) as appropriate on a case-by-case basis.^3,4

Recommended by the ACVIM

VETMEDIN is recommended by the American College of Veterinary Internal Medicine (ACVIM) for use as standard first-line therapy at the onset of clinical signs of CHF.⁵ Read more

Important safety information

The safe use of VETMEDIN has not been established in asymptomatic dogs or heart failure other than AVVI and DCM.

References:

1. Lombard CW, Jöns O, Bussadori CM; for the VetSCOPE Study. Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs. J Am Anim Hosp Assoc. 2006;42(4):249–261. 2. Häggström J, Boswood A, O’Grady M, et al. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study. J Vet Intern Med. 2008;22(5):1124–1135. 3. VETMEDIN® (pimobendan) Chewable Tablets [Freedom of Information Summary]. St. Joseph, MO: Boehringer Ingelheim Vetmedica, Inc.; 2007. 4. VETMEDIN® (pimobendan) Chewable Tablets [package insert]. St. Joseph, MO: Boehringer Ingelheim Vetmedica, Inc.; 2007. 5. Atkins C, Bonagura J, Ettinger S, et al. Guidelines for the diagnosis and treatment of canine chronic valvular heart disease. J Vet Intern Med. 2009;23(6):1142–1150.

Important safety information

VETMEDIN should not be given in case of hypertrophic cardiomyopathy, aortic stenosis, or any other clinical condition where an augmentation of cardiac output is inappropriate for functional or anatomical reasons. The safety of VETMEDIN has not been established in dogs with asymptomatic heart disease or in heart failure caused by etiologies other than atrioventricularvalvular insufficiency or dilated cardiomyopathy. The safe use of VETMEDIN has not been evaluated in dogs younger than 6 months of age, dogs with congenital heart defects, dogs with diabetes mellitus or other serious metabolic diseases, dogs used for breeding, or pregnant or lactating bitches. Use only in dogs with clinical evidence of heart failure. The most common side effects reported in field studies were poor appetite, lethargy, diarrhea, dyspnea, azotemia, weakness, and ataxia. If side effects should occur, pet owners should contact their veterinarian. Please refer to the Full Prescribing Information here.